Estrogen Receptor α Mediates Breast Cancer Cell Resistance to Paclitaxel through Inhibition of Apoptotic Cell Death

Estrogen receptors (ER) are expressed in ∼65% of human breast cancer. Cumulative data from clinical trials and retrospective analyses suggest that some chemotherapeutic agents may be less effective in patients with ER-positive (ER+) tumors than those with ER-negative (ER−) tumors. Paclitaxel is an active agent used in breast cancer chemotherapy. To investigate the possible influence of ER on the therapeutic efficacy of paclitaxel and its underlying mechanism, we established several isogenic ER+ cell lines by stable transfection of ERα expression vectors into ER− breast cancer BCap37 cells. We showed that 17-β estradiol significantly reduces the overall cytotoxicity of paclitaxel in BCap37-expressing ERα but has no influence on the ER− parental cells. Further analyses indicate that expression of ERα in BCap37 cells mainly interferes with paclitaxel-induced apoptotic cell death, without affecting paclitaxel-induced microtubule bundling and mitotic arrest. Moreover, we found that the addition of ICI 182,780 (Fulvestrant), a selective ER down-regulator, could completely reverse the resistance of ER+ BCap37 cells to paclitaxel. These findings showed that ERα-mediated breast tumor cell resistance to paclitaxel was through selective inhibition of paclitaxel-induced tumor cell apoptosis. Additionally, the combination of ICI 182,780 also sensitizes MCF-7 and T47D cell lines to the treatment of paclitaxel, which further confirmed the correlation between ERα and drug resistance in ER+ tumor cells. The results obtained from this study provide useful information for understanding ER-mediated resistance to paclitaxel and possibly other antineoplastic agents. [Cancer Res 2007;67(11):5337–44]

[1]  Y. Luqmani.  Mechanisms of Drug Resistance in Cancer Chemotherapy , 2005, Medical Principles and Practice.

[2]  W. Fan,et al.  Cell Cycle–Dependent Antagonistic Interactions between Paclitaxel and γ-Radiation in Combination Therapy , 2004, Clinical Cancer Research.

[3]  Yi Huang,et al.  Glucocorticoids selectively inhibit paclitaxel-induced apoptosis: mechanisms and its clinical impact. , 2004, Current medicinal chemistry.

[4]  I Nicoletti,et al.  A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. , 1991, Journal of immunological methods.

[5]  S. Ben‐Sasson,et al.  Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation , 1992, The Journal of cell biology.

[6]  G. Franzoso,et al.  Mutual regulation of the transcriptional activator NF-kappa B and its inhibitor, I kappa B-alpha. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[7]  J. Robertson.  Faslodex (ICI 182, 780), a novel estrogen receptor downregulator—future possibilities in breast cancer , 2001, The Journal of Steroid Biochemistry and Molecular Biology.

[8]  C K Osborne,et al.  Selective estrogen receptor modulators: structure, function, and clinical use. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  C. Croce,et al.  Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. , 1996, Cancer research.

[10]  R. Simon,et al.  Association between steroid hormone receptor status and disease-free interval in breast cancer. , 1979, Cancer treatment reports.

[11]  E. Gelmann,et al.  Epidermal growth factor receptor gene expression in estrogen receptor-positive and negative human breast cancer cell lines. , 1987, Molecular endocrinology.

[12]  Donald A. Berry,et al.  Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer , 2006 .

[13]  R. Simon,et al.  The relation between estrogen receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer. , 1978, The New England journal of medicine.

[14]  K. Gelmon.  The taxoids: paclitaxel and docetaxel , 1994, The Lancet.

[15]  R. Sager,et al.  Estrogen inhibits the growth of estrogen receptor-negative, but not estrogen receptor-positive, human mammary epithelial cells expressing a recombinant estrogen receptor. , 1993, Cancer research.

[16]  S. Sukumar,et al.  Polyamine Analogues Down-regulate Estrogen Receptor α Expression in Human Breast Cancer Cells* , 2006, Journal of Biological Chemistry.

[17]  M. J. van de Vijver,et al.  Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome , 2003, British Journal of Cancer.

[18]  Y. Maehara,et al.  Estrogen-receptor-negative breast cancer tissue is chemosensitive in vitro compared with estrogen-receptor-positive tissue. , 1990, European surgical research. Europaische chirurgische Forschung. Recherches chirurgicales europeennes.

[19]  E. Levin,et al.  Plasma membrane estrogen receptors signal to antiapoptosis in breast cancer. , 2000, Molecular endocrinology.

[20]  Mike Clarke,et al.  Polychemotherapy for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[21]  L. Murphy,et al.  New insights into estrogen receptor function in human breast cancer , 2003, Annals of medicine.

[22]  P. Blondeel,et al.  The role of biological markers as predictors of response to preoperative chemotherapy in large primary breast cancer , 2003, Medical oncology.

[23]  W. Fan,et al.  Combination of γ-radiation antagonizes the cytotoxic effects of vincristine and vinblastine on both mitotic arrest and apoptosis , 2005 .

[24]  Korey R. Johnson,et al.  Nuclear Factor-κB/IκB Signaling Pathway May Contribute to the Mediation of Paclitaxel-induced Apoptosis in Solid Tumor Cells , 2000 .

[25]  Yi Huang,et al.  IκB Kinase Activation Is Involved in Regulation of Paclitaxel-Induced Apoptosis in Human Tumor Cell Lines , 2002 .

[26]  Yi Huang,et al.  The possible correlation between activation of NF-kappaB/IkappaB pathway and the susceptibility of tumor cells to paclitaxel-induced apoptosis. , 2002, Oncology research.

[27]  R. Dickson,et al.  Estrogenic regulation of growth and polypeptide growth factor secretion in human breast carcinoma. , 1987, Endocrine reviews.

[28]  Tony Hunter,et al.  Isolation of a human cyclin cDNA: Evidence for cyclin mRNA and protein regulation in the cell cycle and for interaction with p34cdc2 , 1989, Cell.

[29]  W. Fan,et al.  Glucocorticoids interfere with therapeutic efficacy of paclitaxel against human breast and ovarian xenograft tumors , 2006, International journal of cancer.

[30]  H. Lück,et al.  Weekly paclitaxel: an effective and well-tolerated treatment in patients with advanced breast cancer. , 2002, Critical reviews in oncology/hematology.

[31]  Wade V Welshons,et al.  Estrogen Receptor Expression and Sensitivity to Paclitaxel in Breast Cancer , 2004, Cancer biology & therapy.

[32]  R. Dickson,et al.  Antiestrogen resistance in ER positive breast cancer cells , 2004, Breast Cancer Research and Treatment.

[33]  A. Kraft,et al.  Combination of gemcitabine antagonizes antitumor activity of paclitaxel through prevention of mitotic arrest and apoptosis , 2006, Cancer biology & therapy.

[34]  W. Sadee,et al.  Growth factor signaling and resistance to cancer chemotherapy. , 2004, Current topics in medicinal chemistry.

[35]  C. Croce,et al.  Inactivation of Bcl-2 by phosphorylation. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[36]  Baljit Singh,et al.  A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[37]  J. Kurebayashi,et al.  Endocrine-resistant breast cancer: Underlying mechanisms and strategies for overcoming resistance , 2003, Breast cancer.

[38]  B. Park,et al.  Physiologic estrogen receptor alpha signaling in non-tumorigenic human mammary epithelial cells , 2006, Breast Cancer Research and Treatment.

[39]  Richard L Schilsky,et al.  Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  C. Redmond,et al.  Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: findings from National Surgical Adjuvant Breast and Bowel Project Protocol B-06. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.